Phase III Beckons For Kiadis In Unmatched Bone Marrow Transplant Patients
This article was originally published in Scrip
Executive Summary
Kiadis Pharma N.V. has presented positive data from its single dose Phase II trial with lead product ATIR101 for the treatment of blood cancers, clearing the way for the start of a randomized Phase III in the second half of the year. The trial met the primary endpoint of transplant-related mortality (TRM) at six months.